ArticleDiabetology & metabolic syndrome2025
Decoding survival in MASLD: the dominant role of metabolic factors.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Association of serum uric acid and serum uric acid/creatinine ratio with metabolic dysfunction-associated fatty liver disease in young adults: a retrospective study.BMC endocrine disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic factors are considered to influence disease progression in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), but the impact of individual metabolic factors on the survival rate of patients with MASLD is still unclear.
aimsThis article aims to reveal how metabolic components affect the survival of patients with this disease.
methodsA total of 3,086 participants with MASLD based on the diagnostic criteria established at the Delphi conference from NHANES III were included in this analysis. COX regression model (C-index = 0.64) was used to analyze the all-cause and attributable mortality of different number of metabolic factors. Elastic Network Regression model (C-index = 0.69), Accelerated Failure Time model and Randomized Survival Forest model (C-index = 0.63) based on machine learning were used to analyze the weight of each metabolic factor, and a Metabolism-related survival risk score formula was established and verified.
resultsThis study found that not only the number of metabolic factors had different effects on all-cause survival in MASLD patients, but also the degree of impact of different metabolic factors on survival was quite different, among which poor glycemic control was the most important influencing factor.
conclusionThis study highlights the clinical value of relevant metabolic factors in predicting survival in the MASLD patient population. Related metabolic factors can be used as surrogate biomarkers for the follow-up of MASLD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.